EIGA (Inflammatory Bowel Disease Group of Galicia), Santiago de Compostela, Spain.
Inflamm Bowel Dis. 2010 Jul;16(7):1227-38. doi: 10.1002/ibd.21170.
Clinical and therapeutic patterns of ulcerative colitis (UC) are variable in different world regions. The purpose of this study was to examine two close independent southern European UC populations from 2 bordering countries and observe how demographic and clinical characteristics of patients can influence the severity of UC.
A cross-sectional study was conducted during a 15-month period (September 2005 to December 2006) based on data of 2 Web registries of UC patients. Patients were stratified according to the Montreal Classification and disease severity was defined by the type of treatment taken.
A total of 1549 UC patients were included, 1008 (65%) from northern Portugal and 541 (35%) from Galicia (northwest Spain). A female predominance (57%) was observed in Portuguese patients (P < 0.001). The median age at diagnosis was 35 years and median years of disease was 7. The majority of patients (53%) were treated only with mesalamine, while 15% had taken immunosuppressant drugs, and 3% biologic treatment. Most patients in both groups were not at risk for aggressive therapy. Extensive colitis was a predictive risk factor for immunosuppression in northern Portugal and Galicia (odds ratio [OR] 2.737, 95% confidence interval [CI]: 1.846-4.058; OR 5.799, 95% CI: 3.433-9.795, respectively) and biologic treatment in Galicia (OR 6.329, 95% CI: 2.641-15.166). Younger patients presented a severe course at onset with more frequent use of immunosuppressors in both countries.
In a large population of UC patients from two independent southern European countries, most patients did not require aggressive therapy, but extensive colitis was a clear risk factor for more severe disease.
溃疡性结肠炎（UC）的临床和治疗模式在不同的世界区域存在差异。本研究的目的是研究来自两个接壤国家的两个密切独立的南欧 UC 人群，并观察患者的人口统计学和临床特征如何影响 UC 的严重程度。
这是一项在 15 个月期间（2005 年 9 月至 2006 年 12 月）进行的横断面研究，基于两个 UC 患者网络注册的数据分析。根据蒙特利尔分类对患者进行分层，并根据所采取的治疗类型定义疾病严重程度。
共纳入 1549 例 UC 患者，其中 1008 例（65%）来自葡萄牙北部，541 例（35%）来自加利西亚（西班牙西北部）。葡萄牙患者中观察到女性为主（57%）（P < 0.001）。诊断时的中位年龄为 35 岁，中位疾病年限为 7 年。大多数患者（53%）仅接受美沙拉嗪治疗，15%接受免疫抑制剂治疗，3%接受生物治疗。两组中大多数患者都没有接受强化治疗的风险。葡萄牙北部和加利西亚的广泛性结肠炎是免疫抑制治疗的预测风险因素（优势比[OR] 2.737，95%置信区间[CI]：1.846-4.058；OR 5.799，95% CI：3.433-9.795），加利西亚的生物治疗（OR 6.329，95% CI：2.641-15.166）。两国年轻患者的发病初期病情较重，更常使用免疫抑制剂。
在来自两个独立的南欧国家的大量 UC 患者中，大多数患者不需要强化治疗，但广泛性结肠炎是疾病更严重的明确危险因素。
